Fluzoparib; Apatinib

DRUG2 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

Conditions

Fallopian Tube CancerOvarian CancerPrimary Peritoneal CarcinomaTreatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Phase 3

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

Jiangsu HengRui Medicine Co., Ltd.Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma

Start: 2020-06-02End: 2024-04-01Updated: 2022-04-25

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Jiangsu HengRui Medicine Co., Ltd.Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Start: 2020-07-13End: 2025-06-30Target: 474Updated: 2020-08-10

Related Papers

Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial.

2025-12-01

A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.

2023-09-2911 citations